Roche’s Vision Loss Therapy to Compete With Regeneron’s Blockbuster

The FDA has approved Roche’s Vabysmo (faricimab-svoa) for treating the two most common forms of vision loss, paving the way for the drug to go head-to-head with Regeneron Pharmaceuticals’ blockbuster, Eylea (aflibercept).
Source: Drug Industry Daily